In a study conducted by Chou et al. in 2016, with a percentage of 34% T2DM patients, FGF21 was non-inferior to NT pro BNP in diagnosing diastolic dysfunction and predicting cardiovascular events over a 1-year follow up [27]. This evidence concerns the gene FGF21 and type 2 diabetes mellitus.